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Protein hypercatabolism significantly contributes to the onset and progression of
muscle wasting in cancer cachexia. In this regard, a major role is played by the
ATP-ubiquitin-proteasome-dependent pathway and by autophagy. However, little is
known about the relevance of the Ca2+-dependent proteolytic system. Since previous
results suggested that this pathway is activated in the skeletal muscle of tumor hosts, the
present study was aimed to investigate whether inhibition of Ca2+-dependent proteases
(calpains) may improve cancer-induced muscle wasting. Two experimental models of
cancer cachexia were used, namely the AH-130 Yoshida hepatoma and the C26 colon
carcinoma. The Ca2+-dependent proteolytic systemwas inhibited by treating the animals
with dantrolene or by overexpressing in the muscle calpastatin, the physiologic inhibitor
of Ca2+-dependent proteases. The results confirm that calpain-1 is overexpressed and
calpastatin is reduced in the muscle of rats implanted with the AH-130 hepatoma, and
show for the first time that the Ca2+-dependent proteolytic system is overactivated
also in the C26-bearing mice. Yet, administration of dantrolene, an inhibitor of the
Ca2+-dependent proteases, did not modify tumor-induced body weight loss and muscle
wasting in the AH-130 hosts. Dantrolene was also unable to reduce the enhancement
of protein degradation rates occurring in rats bearing the AH-130 hepatoma. Similarly,
overexpression of calpastatin in the tibialis muscle of the C26 hosts did not improve
muscle wasting at all. These observations suggest that inhibiting a single proteolytic
system is not a good strategy to contrast cancer-induced muscle wasting. In this regard,
a more general and integrated approach aimed at targeting the catabolic stimuli rather
than the proteolytic activity of a single pathway would likely be the most appropriate
therapeutic intervention.
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INTRODUCTION
Cachexia is a wasting syndrome that frequently occurs in cancer
patients, worsening both their prognosis and quality of life and
significantly reducing survival rate. Although at different degrees,
virtually all body compartments are affected by cachexia, the
skeletal muscle being among the most compromized. Previous
studies showed that cancer-induced muscle wasting mainly
derives from acceleration of protein breakdown rates. The main
proteolytic systems operating in the muscle were all found
hyperactivated in tumor hosts, suggesting that they could be
considered as potential therapeutic targets (reviewed in Argilés
et al., 2014). Recent reports however, showed that inhibition of
proteasome-dependent proteolysis or autophagy was not able to
improve muscle wasting in tumor-bearing animals (Penna et al.,
2013, 2016).
The contribution of proteasomes and autophagy to the onset
and progression of cancer-induced muscle wasting was deeply
investigated, however quite little is known about the Ca2+-
dependent proteolytic system.
Calpains (EC 3.4.22.17) are a family of Ca2+-dependent
cysteine proteases. Three members of this family are mainly
expressed in the skeletal muscle, namely the ubiquitous µ- and
m-calpains and the muscle-specific p94 calpain (also known
as calpains-1, -2, and -3). Both µ- and m- calpains consist
of two subunits of 80 and 30 kDa, respectively (reviewed in
Ono et al., 2016). The former (constituted by four domains)
contains the catalytic cleft, whereas the latter (two domains) is
endowed with regulatory functions. The p94 calpain also includes
three insertions that are not shared with other calpains. When
intracellular Ca2+ concentrations increase, inactive calpains,
normally localized in the cytosolic compartment, translocate to
the cell membrane and the 80 kDa subunit is converted by
autoproteolysis to a 75 kDa form. A number of cytoskeletal
proteins were proposed as substrates of calpains, among which
desmin, dystrophin, fodrin, myosin, troponins I, and T (reviewed
in Ono et al., 2016). Other reports showed that also calpastatin,
the physiologic inhibitor of calpains, and the plasmamembrane
130 kDa Ca2+-ATPase are cleaved by Ca2+-dependent proteases
(Pontremoli et al., 1991; Salamino et al., 1992; Ono et al., 2016).
The physiological relevance of calpains is demonstrated by
their involvement in several processes such as cell proliferation,
differentiation, migration, apoptosis, and aging. Ca2+-dependent
proteases were also proposed to contribute to different
pathologies. A cause-effect relationship was established among
calpain deficiencies and diseases, for this reason defined
calpainopathies (Ono et al., 2016). As for cancer cachexia,
increased calpain mRNA levels were reported in the skeletal
muscle of animals bearing the AH-130 hepatoma (Busquets
et al., 2000). The contribution of calpain activity to muscle
wasting induced by tumor growth in rats bearing the Yoshida
AH-130 hepatoma was suggested by the progressive reduction
of both calpastatin and the 130 kDa Ca2+-ATPase levels
(Costelli et al., 2001), as well as by the increased cleavage in
vitro of specific fluorogenic substrates (Costelli et al., 2002;
Borges et al., 2014). More recently increased calpain expression
was reported in the muscle of tumor-bearing rats treated
with sorafenib (Toledo et al., 2016). In patients with cancer,
however, both increased or unchangedmuscle calpain levels were
observed (Smith et al., 2011; Tardif et al., 2013). Differencies
in tumor type and disease severity likely account for such
discrepancies.
Although a number of data support the involvement
of Ca2+-dependent proteolysis in cancer cachexia, protein
hypercatabolism was not suppressed in muscles isolated from
tumor-bearing animals and exposed to calpain inhibitors
(Temparis et al., 1994; Baracos et al., 1995; Llovera et al.,
1995). Such studies, however, were performed on preparations of
isolated muscles incubated in the presence of calpain inhibitors,
which is a rather non-physiological setting. Previous studies from
our laboratory showed that leupeptin, an inhibitor of cysteine
proteases including calpains and many lysosomal cathepsins,
improved muscle wasting in rats bearing the AH-130 hepatoma
(Tessitore et al., 1994).
On the whole, while some evidences do not support a role
of calpain system in cancer-associated muscle wasting, other
findings suggest the opposite. Thus, the working hypothesis in
the present study is that specific inhibition of calpain activity
could be a means to prevent, or at least delay, muscle wasting that
occurs in cancer cachexia. Along this line, the calpain system was
modulated in tumor-bearing animals either by pharmacological
or genetic means.
MATERIALS AND METHODS
Reagents
All reagents supplied by Sigma-Aldrich (St. Louis, MO, USA),
unless differently specified.
Animals and Treatments
MaleWistar rats (5 weeks old/150 g) ormale Balb/cmice (5 weeks
old/20 g) were provided by Charles River, Calco, Italy. They were
housed on a regular dark-light cycle (light from 08:00 to 20:00),
with free access to food and water, and cared for in compliance
with the Italian Ministry of Health Guidelines and the Policy
on Humane Care and Use of Laboratory Animals (NIH, 1996).
The experimental protocol was approved by the Bioethical
Committee of the University of Turin. Both rats and mice were
randomized into two groups, namely controls and tumor hosts.
As for rats, (n = 8) they were injected intraperitoneally (i.p.)
with 108 AH-130 Yoshida ascites hepatoma cells, whereas tumor-
bearing mice (n = 6) were subcutaneously (s.c.) inoculated
between the shoulder blades with 5 × 105 Colon 26 (C26)
carcinoma cells. Control animals (rats: n = 8; mice: n =
6) received saline, i.p. or s.c. In a second experiment rats
were divided into four groups (n = 8): Controls, dantrolene
treated controls, AH-130 hosts and dantrolene-treated AH-
130 hosts. Dantrolene (10 mg/kg b.w.) was daily administered
s.c., starting on the day of tumor transplantation. Finally,
another experiment using the C26 tumor was performed. the
animals were divided into two groups, namely controls (C)
and tumor hosts (C26). Each group was further divided into
transfected (n = 6 for both C and C26) and untransfected
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(n = 6 for both C and C26). Transfection procedure is described
below.
AH-130 hosts and C26-bearing mice were euthanized under
isoflurane anesthesia. The former were sacrificed at days 4 or 7
after tumor transplantation, while sacrifice time for the latter was
day 14 of tumor growth. Several muscles and organs were rapidly
excised, weighed, frozen in isopentane cooled with liquid N2, and
stored at−80◦C for subsequent analysis.
Histological Analysis
Serial 10 µm-thick frozen sections were cut from cryopreserved
tissue blocks, adhered to Superfrost Plus microscopy slides and
stained with hematoxylin and eosin. All sections were examined
by light microscopy (Nikon Eclipse TS100) and digital images
were obtained with a Nikon COOLPIX 4500 camera. To assess
myofiber cross sectional area (CSA) ∼300–400 fibers of tibialis
anterior muscle sections were counted and measured using
the Image J software (http://rsb.info.nih.gov/ij/; NIH, Bethesda,
MD).
For immunofluorescence, transverse sections were fixed
in 4% paraformaldehyde and probed with the primary anti-
calpastatin mAb 35,23 (1:200 Melloni et al., 2006). Detection
was performed using a FITC-conjugated mouse IgG secondary
antibody (1:2,000; Bio-Rad Laboratories, Hercules, CA).
Nuclei were stained with the DAPI fluorochrome and the
images captured with a Nikon COOLPIX 4500 camera in an
epiilluminated fluorescence microscope (Axiovert 35, Zeiss,
Germany).
Protein Turnover
Muscle protein turnover rates were determined as previously
described (Costelli et al., 1993). Briefly, rats received an i.p.
dose of NaH14CO3 (250 µCi/kg b.w.) 24 h before tumor
transplantation. They were then sacrificed at days 0 and 7 after
tumor inoculation and total protein radioactivity determined.
Briefly, gastrocnemius was rapidly weighed and homogenized
to 10% (wt/vol) in chilled water. Total protein content was
determined by the method of Lowry et al. (1951) using bovine
serum albumin as working standard. Trichloroacetic acid-
insoluble proteins were processed for lipid extraction, extensively
hydrolyzed, and counted in a liquid scintillation spectrometer
to obtain total protein radioactivity. Fractional rates of protein
degradation (kd) were calculated as follows and expressed as
%/day:
kd = ln(total protein radioactivity)/t.
Calpastatin Transfection
RNCAST600 cloned in pEYFP-C1 (De Tullio et al., 2009) was
used to express a calpastatin form containing the regulatory L-
domain and a single inhibitory unit. The left tibialis anterior
muscle was injected with 25 µl of 0.5 U/µl hyaluronidase (to
improve transfection efficiency) and 2 h later injected with 50
µg of plasmidic DNA, while the contralateral muscle served as
control. One minute following DNA injection transcutaneous
pulses were applied by two stainless steel plate electrodes (gap
between plates: 4 mm). Electrical contact with the leg skin
FIGURE 1 | Calpain and calpastatin expression in controls and rats bearing the AH-130 hepatoma. (A) Calpain protein expression in tibialis muscles of
controls and AH-130 tumor-bearing rats after 4 and 7 days from tumor inoculation. (B) Calpastatin protein expression in tibialis muscles of controls and AH-130
tumor-bearing rats after 4 and 7 days from tumor inoculation. Densitometric quantifications (histograms) were normalized according to tubulin levels. Blot
representative patterns are shown. Data (mean ± SD, n = 8) are expressed as % of controls. Significance of the differences (ANOVA): *p < 0.05; **p < 0.01 vs.
controls.
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was assured by shaving each leg and applying conductive gel.
Electric pulses with a standard square wave were delivered by an
electroporator (ECM-830, BTX-Harvard Apparatus, Holliston,
MA, USA). Three pulses (20 ms each) of 75 V/cm were
administered to the muscle with a delivery rate of 1 pulse/s.
The polarity was then reversed and a further three pulses were
delivered to the muscle. Electroporation was performed 10
days before animal sacrifice. With the transfection procedure
described, no sign of muscle damage and inflammatory infiltrate
could be seen by histological analysis (Penna et al., 2010).
The expression of YFP-RNCAST600 was confirmed by western
blotting (see below), using an anti-GFP antibody (Figure S1;
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Western Blotting
Approximately 50mg of gastrocnemius or 25mg of tibialis
muscle were homogenized in 80 mmol/L Tris-HCl, pH 6.8,
containing 100 mmol/L dithiothreitol, 70 mmol/L SDS, and 1
mmol/L glycerol, with freshly added protease and phosphatase
inhibitor cocktails; kept on ice for 30 min; centrifuged at
15,000 × g for 10 min at 4◦C and the supernatant collected.
Protein concentration was assayed according to Bradford, using
bovine serum albumin as working standard. Equal amounts of
protein (30 µg) were heat-denaturated in sample-loading buffer
(50 mmol/L Tris-HCl, pH 6.8, 100 mmol/L dithiothreitol, 2%
SDS, 0.1% bromophenol blue, 10% glycerol), resolved by SDS-
PAGE, and transferred to nitrocellulose membranes (Bio-Rad
Laboratories, Hercules, CA). The filters were blocked with Tris-
buffered saline containing 0.05% Tween and 5% non-fat dry milk
and then were incubated overnight with a mouse monoclonal
anti-calpain-1 antibody (1:1000; Chemicon, Temecula, CA, USA,
Milan, Italy), recognizing the catalytic subunit (∼80 kDa) of
calpain-1; a commercial anti-calpastatin antibody recognizing
the whole protein (1:200; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and the monoclonal anti-calpastatin antibody mAb
35,23 recognizing also the partially digested forms of calpastatin
(1:1,000; provided by R. De Tullio, characterization described in
Melloni et al., 2006); an antibody against tubulin (1:8,000, mouse
monoclonal antibody, clone T5168); or GAPDH (1: 5,000, goat
polyclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA).
FIGURE 2 | Calpain and calpastatin expression in control animals and in mice implanted with the C26 tumor. Calpain protein levels in the tibialis muscle (A)
and in the heart (B) of controls and C26 hosts. (C) Calpastatin digestion products were detected in the tibialis muscle of controls and C26 tumor-bearing mice by the
mAb 35,23. (D) Immunofluorescence images of tibialis muscle sections in controls and C26-bearing mice stained for calpastatin (green) and nuclei (blue).
Densitometric quantifications (histograms) were normalized according to tubulin levels. Blot representative patterns are shown. Data (mean ± SD, n = 6) are
expressed as % of controls. Significance of the differences (t-test): ***p < 0.001 vs. controls.
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Peroxidase-conjugated IgGs (Bio-Rad Laboratories, Hercules,
CA) were used as secondary antibody. For quantification,
performed by densitometric analysis (TotalLab; Non-linear
Dynamics, Newcastle on Tyne, UK), samples were run on a single
gel (representative patterns shown in Figures) and normalized
against tubulin or GAPDH levels.
Data Analysis and Presentation
Results are expressed as means ± SD. The significance of the
differences was evaluated by analysis of variance (ANOVA)
followed by Tukey’s test or by Student’s “t”-test (indicated in
Figure legend). As for the fractional rates of protein turnover, the
significance of the differences was calculated by comparing linear
regression by ANOVA (Lee and Lee, 1982).
RESULTS
Rats bearing the Yoshida AH-130 hepatoma and mice implanted
with the C26 colon carcinoma show a marked loss of both body
weight andmusclemass (Costelli et al., 1993; Bonetto et al., 2009).
Skeletal muscle wasting is associated with enhanced activity
of the Ca2+-dependent proteolytic system. In the muscle of
rats bearing the AH-130 hepatoma, the levels of calpain-1
are increased while those of the endogenous specific inhibitor
calpastatin are reduced (Figures 1A,B; Costelli et al., 2001).
Similarly, calpain-1 levels are increased in both the tibialis
anterior (Figure 2A) and heart (Figure 2B) of mice implanted
with the C26 tumor. In parallel, digestion products of calpastatin,
markers of calpain activity (De Tullio et al., 2000), accumulate
in the muscle of C26 hosts (Figure 2C and Figure S1). Finally,
in these latter calpastatin is diffused in the cytosol (Figure 2D),
a localization that is associated with calpain activation and Ca2+
increase (De Tullio et al., 1999).
To understand if interfering with the activity of the Ca2+-
dependent proteolytic system can antagonize cancer-induced
muscle wasting, rats bearing the AH-130 hepatoma were treated
with dantrolene, a molecule that inhibits Ca2+ release from
the sarcoplasmic reticulum, thus reducing calpain activation
(Perry et al., 2010; Malvestio et al., 2016). The results show that
dantrolene administration did not prevent either the loss of body
and muscle weight (Figure 3A and Table S1) or the acceleration
of protein breakdown rates (Figure 3B). No appreciable effects of
dantrolene could be observed on tumor mass (total cell number:
1,198 × 106 ± 239 and 1,480 × 106 ± 359 in untreated and
treated AH-130 hosts, respectively) and on food intake (C = 136
± 17 g, C+ dantrolene= 129± 22 g, AH-130= 94± 10 g, AH-
130+ dantrolene= 85± 16 g, p < 0.01 tumor hosts vs. controls,
irrespective of treatment). In addition, dantrolene did not exert
any effect on control rats (Figure 3). Similar data were obtained
using a cell-permeable calpain inhibitor (Figure S2).
The use of systemic inhibitors is limited by pharmacokinetics,
biological effective dose and potential toxicity. For this reason, as
FIGURE 3 | Effects on treatment with dantrolene on muscle weight and protein degradation rates in rats bearing the AH-130 hepatoma. (A) Body weight
(b.w.), gastrocnemius (GSN), soleus, and heart weight in controls and AH-130 tumor-bearing rats. The data are reported as % of controls (mean ± SD, n = 8).
Significance of the differences (ANOVA): *p < 0.05 vs. controls. (B) Fractional rates of protein degradation in the gastrocnemius muscle, expressed as % day (mean ±
SD, n = 8), in controls and AH-130 hosts, treated or not with dantrolene. Significance of the differences (linear regression comparison; see Materials and Methods):
*p < 0.05 vs. controls.
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a second strategy to specifically target calpain activity locally in
the skeletal muscle, a gene approach aimed at hyperexpressing
calpastatin was used. The left tibialis anterior muscle of mice
bearing the C26 tumor was transfected with an expression vector
encoding a calpastatin species containing, in addition to a single
inhibitory unit, also the regulatory L-domain (RNCAST600;
transfection efficiency: 30%). The transfected sequence, even if
produced as a fusion protein with the YFP tag at the C-terminus,
maintains the ability to inhibit calpain activity (Figure S3;
De Tullio et al., 2009). Being muscle transfection localized
unilaterally to the tibialis anterior, no effects on body weight were
observed, as expected (Figure 4A). RNCAST600 overexpression,
however, was also unable to interfere with both loss of muscle
mass (Figure 4B, Figure S4; Table S2) and changes of myofiber
cross sectional area (CSA; Figure 5, Figure S4). A tendency
to reduce muscle mass that does not reach significance, could
be observed in control mice receiving electroporation. Despite
not significant, such reduction in size could suggest that the
transfection procedure might have produced a systemic reaction,
likely of inflammatory nature, that could slightly affect the
whole muscle compartment and that could have been partially
FIGURE 4 | Calpastatin overexpression in the tibialis muscle of
controls and C26 hosts. (A) Body weight of controls and C26-bearing mice
transfected (RNCAST600) and untransfected. The data are reported as % of
controls (means ± SD; d0 C = 18.72 ± 0.373 g). (B) Gastrocnemius (GSN)
and tibialis muscle weight. Data are expressed as % of controls (mean ± SD,
n = 8). Significance of the differences (ANOVA): *p < 0.05; ***p < 0.001 vs.
controls, $$$p < 0.001 vs. RNCAST600.
antagonized in tumor hosts. However, the observation that
no differences were observed in terms of CSA (Figure 5B,
Figure S4) supports the lack of effectiveness of RNCAST600
overexpression in preventing C26-induced muscle atrophy.
RNCAST600 overexpression did not affect tumor mass (C26 =
355± 61 mg, C26-RNCAST600= 326± 58 mg).
DISCUSSION
The results shown in the present study demonstrate that the
expression of molecules pertaining to the calpain-dependent
proteolytic pathway is altered in the muscle of tumor hosts,
indicating an enhanced activity of this system and confirming
previous reports (Costelli et al., 2005). Most importantly,
however, inhibiting this proteolytic system does not contrast
cancer-induced muscle wasting.
By all available evidence, the calpain system does not
contribute significantly to bulk protein degradation, but only
performs a limited proteolysis of substrates. Along this line,
in normal conditions of calcium homeostasis calpains basically
FIGURE 5 | Myofiber cross-sectional area. (A) Representative histological
pattern (hematoxylin and eosin staining) of transfected and untransfected
muscles. (B) Morphometric analysis performed on hematoxylin and eosin
stained sections of tibialis muscle derived from controls and C26
tumor-bearing mice untransfected or transfected with RNCAST600. Data
(mean ± SD, n = 8) are expressed as percentages of controls. Significance of
the differences (ANOVA): **p < 0.01 vs. controls.
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exert a processing rather than a degradative action aimed to
induce functional modifications in the target proteins (Goll
et al., 2003). Calpains directly recognize substrates, differently
from the lysosomal and the proteasomal systems that need
ubiquitylation or sequestration into autophagosomes to tag
their substrates (Goll et al., 2003). It is now well-accepted,
in this regard, that while calpains are required to initiate the
degradation of myofibrillar proteins, they are not involved in
the bulk degradation of sarcoplasmic or sarcolemmal proteins
(Huang and Zhu, 2016). Calpains appear to sever thick and
thin filaments from myofibrils, thereby permitting a subsequent
step in which suitable protein substrates are allowed to gain
access to the degradative machinery (proteasome and lysosomal-
dependent systems: Reviewed in Huang and Zhu, 2016). The
activity of such a physiologically operating pathway can be
enhanced by homeostasis alterations. As an example, oxidative
stress was shown to increase calpain expression in cultured
myocytes (Dargelos et al., 2010) and to induce the degradation of
myofibrillar proteins (Smuder et al., 2010). Of interest, oxidative
stress was shown to occur in the skeletal muscle of cachectic
tumor-bearing animals (Mastrocola et al., 2008; Assi et al., 2016).
The calpastatin construct (RNCAST600) used in the present
study encodes a single inhibitory unit and a complete regulatory
L-domain. Previous data show that YFP-tagged RNCAST600
retains its ability to inhibit calpain activity (Stifanese et al., 2008;
De Tullio et al., 2009) and since it contains the L domain,
it can bind calpain also in the inactive form (Melloni et al.,
2006). In addition, we have here observed that 1 week after
transfection RNCAST600 is still expressed, not degraded, and
effectively inhibits calpain activity (Figure S1). The lack of effect
of RNCAST600 in preventing cancer-induced muscle wasting
could depend on a sort of “calpastatin resistance”. A loss of
inhibitory efficiency, that allows calpain to be active even at high
concentrations of calpastatin, was previously observed in those
calpastatin forms containing also the regulatory region (XL-L and
L-domains; De Tullio et al., 2014). Following [Ca2+]i increase,
calpastatin, that is normally localized in perinuclear aggregates,
diffuses in the cytosol and interacts with active calpain. Such
diffusion can be reversed, even in the presence of Ca2+, if exon
6-containing calpastatins are phosphorylated by PKA (De Tullio
et al., 1999). This process ultimately leaves active calpain free
to operate on its targets even in the presence of high amounts
of inhibitor. The possibility that these regulations contribute to
the lack of effect of calpastatin overexpression in the muscle of
the C26 hosts cannot be discarded. Future challenges will be to
explore whether the transfection of different forms of calpastatin
(i.e., without L-domain or with an L-domain lacking exon 6)
could affect cancer-induced muscle wasting.
In addition to myofibrillar protein degradation, calpain
activation also positively modulates endoplasmic reticulum (ER)
stress (Muruganandan and Cribb, 2006; Langou et al., 2010).
Muscle wasting induced by cancer was enhanced by inhibiting
both ER stress and unfolding protein response (UPR) (Bohnert
et al., 2016). An intriguing speculation, in this regard, is that
calpain inhibition could result in reduced myofilament release
from sarcomeres, but also in ER stress and UPR down-regulation
(Isaac et al., 2016), still shifting protein turnover toward
degradation.
FIGURE 6 | Maintenance of proteostasis after calpain inhibition. (A) In normal conditions calpains contribute, together with other systems such as caspases, to
the degradation of myofibrillar proteins by severing thick and thin filaments from myofibrils, providing substrates for both proteasome and lysosomal-dependent
systems. (B) When calpains are inhibited, pharmacologically or by genetic manipulation, the activity of both lysosomes and proteasomes is likely enhanced, in the
attempt to maintain the physiological rates of protein degradation.
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The results shown in the present study support the
consolidating notion that modulating the activity of a single
proteolytic system would not be an adequate strategy to defeat
cachexia. Indeed, previous reports showed that proteasome
specific inhibition was unable as well to counteract muscle
wasting in animals bearing experimental tumors (Fermoselle
et al., 2013; Chacon-Cabrera et al., 2014; Penna et al., 2016). This
is not totally unexpected, taking into consideration that muscle
protein homeostasis (proteostasis) results from the convergent
regulation of protein synthesis and degradation rates. These
latter depend on the activity of the whole protein catabolic
machinery, with the proteolytic pathways acting in concert,
thereby providing substrates for de novo protein synthesis and
energy production.
The interplay among the different proteolytic systems
likely allows the myofiber to preserve proteostasis. If a
single proteolytic pathway is failing, the others might well-
increase their activity, aiming to maintain the fractional
degradation rates at physiological levels (Figure 6). As an
example, inhibition of the ubiquitin-proteasome system led to
increased autophagy, while proteasome-dependent proteolysis
was activated when autophagy was blocked (Yamaguchi et al.,
2012). Similarly, calpain inhibition induced autophagy by
reducing the levels of the Atg12-Atg5 conjugate and/or by
degrading beclin-1 (Yamaguchi et al., 2012). The exogenous
inhibition of a single proteolytic pathway could be associated
with inefficient disposal of altered proteins/organelles by the
other systems, overcoming the ability to maintain myofiber
homeostasis, thus contributing to the wasting phenotype.
Such a hypothesis appears particularly intriguing in cancer
cachexia, where, in face of enhanced bulk proteolysis, the
autophagic-lysosomal system is not able to efficiently get rid
of accumulated proteins (Penna et al., 2013; Pigna et al.,
2016).
On the whole, accumulating evidence indicate that most of
the components of the muscle proteolytic machinery (calpains,
proteasomes, lysosomes) are overexpressed in cancer cachexia,
while systems involved in the endogenous control of protein
turnover, such as calpastatin and deubiquitylating enzymes (Goll
et al., 2003; Wing, 2016) are down-regulated. These changes are
often considered as controlling events, however they might well-
reflect an adaptive response to sustained hypercatabolic stimuli.
The above reported observation that calpains appear to act
upstream of both proteasome and lysosomal proteolysis supports
the existence of a hierarchy in the hypercatabolic response in
muscle wasting. In this regard, (upstream) therapeutic strategies
should be focused on the real trigger(s) and on controlling events
rather than on the single (downstream) proteolytic pathways.
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